HOME >> BIOLOGY >> NEWS
Reactivated gene shrinks tumors

CAMBRIDGE, Mass. -- Many cancers arise due to defects in genes that normally suppress tumor growth. Now, for the first time, MIT researchers have shown that re-activating one of those genes in mice can cause tumors to shrink or disappear.

The study offers evidence that the tumor suppressor gene p53 is a promising target for human cancer drugs.

"If we can find drugs that restore p53 function in human tumors in which this pathway is blocked, they may be effective cancer treatments," said David Kirsch of MIT's Center for Cancer Research and Harvard Medical School, one of the lead co-authors of the paper.

The study will be published in the Jan. 24 online edition of Nature. It was conducted in the laboratory of Tyler Jacks, director of the Center for Cancer Research, the David H. Koch Professor of Biology and a Howard Hughes Medical Institute investigator.

P53 has long been known to play a critical role in the development of many tumors-it is mutated in more than 50 percent of human cancers. Researchers have identified a few compounds that restore p53 function, but until now, it has not been known whether such activity would actually reverse tumor growth in primary tumors.

The new MIT study shows that re-activating p53 in mouse tumors dramatically reduces the size of the tumors, in some cases by 100 percent.

"This study provides critical genetic evidence that continuous repression of a tumor suppressor gene is required for a tumor to survive," said Andrea Ventura, an Italian postdoctoral associate in the Center for Cancer Research and first author of the paper.

In normal cells, p53 controls the cell cycle. In other words, when functioning properly, it activates DNA repair mechanisms and prevents cells with damaged DNA from dividing. If DNA damage is irreparable, p53 induces the cell to destroy itself by undergoing apoptosis, or programmed cell death.

When p53 is turned off by mutation or
'"/>

Contact: Elizabeth Thomson
thomson@mit.edu
617-258-5402
Massachusetts Institute of Technology
24-Jan-2007


Page: 1 2 3

Related biology news :

1. Chemotherapy drug shrinks brain tumors
2. Overfishing large sharks impacts entire marine ecosystem, shrinks shellfish supply
3. Brains fear center likely shrinks in autisms most severely socially impaired
4. Ultrasounds show mothers drinking shrinks fetal brain
5. Melatonin shrinks bird gonads. What does the popular supplement do in humans?
6. Invasion of the brain tumors
7. A friendly foe -- Bacteria residing in the gut boost immune response to tumors
8. Nanoparticles carry chemotherapy drug deeper into solid tumors
9. Frog molecule could provide drug treatment for brain tumors
10. Study could impact noninvasive treatment of cancer tumors
11. Talcum powder stunts growth of lung tumors

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/8/2017)... 7, 2017 The biometrics market has ... confluence of organizations, desires to better authenticate or ... (password and challenge questions), biometrics is quickly working ... The market is driven by use cases, though ... and enterprise uses cases, with consumer-facing use cases ...
(Date:2/7/2017)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the latest release of ... and award winning eClinical solution, is now available for ... a proven Software-as-a-Service (SaaS) clinical research technology platform that ... delivers an entire suite of eClinical tools to support ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... ... March 21, 2017 , ... Watson-Marlow ... pump with patented ReNu single-use (SU) cartridge technology. Engineered by the world ... pumps in SU tangential flow filtration (TFF), virus filtration (VF) and high-performance ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Society for Immunotherapy ... as outlined in the Administration’s recently published fiscal year 2018 budget request. , ... of Health (NIH) by $5.8 billion or roughly 20% of its total budget. If ...
(Date:3/22/2017)... and PETACH TIKVAH, Israel , ... BCLI), a leading developer of adult stem cell technologies ... , Chief Executive Officer, will provide an update on ... 2 nd Annual Neuroscience Biopartnering and Investment Forum, ... New York Academy of Sciences. ...
(Date:3/22/2017)... , March 22, 2017  RXi Pharmaceuticals ... innovative therapeutics that address significant unmet medical needs, ... Chief Business Officer, will present at the 5th ... will provide a platform to present to and ... leading pharmaceutical and biotech companies as well as ...
Breaking Biology Technology:
Cached News: